Houston-based Decisio's virtual care technology has been paired with GE Healthcare and Microsoft technology in a new initiative for hospitals dealing with the COVID-19 outbreak. Photo via decisiohealth.com

Houston-based health tech startup Decisio Health Inc. has been enlisted in the war against the novel coronavirus.

Chicago-based GE Healthcare Inc. has tapped Decisio's AI-powered DECISIOInsight software, which enables health care providers to remotely monitor patients, for an initiative involving Redmond, Washington-based Microsoft Corp. that's designed to help treat COVID-19 patients.

The coronavirus-targeted Mural Virtual Care Solution, which was introduced April 15, marries Decisio's virtual monitoring software with GE Healthcare's telehealth technology and Microsoft's Azure cloud-computing platform. It's designed to offer hospitals a broad view of COVID-19 patients who are hooked up to ventilators in ICUs. This platform merges data from ventilators, patient monitoring systems, electronic health records, labs, and other sources.

This special technology package is a stripped-down version of the Mural Virtual Care Solution, which pairs Decisio's and GE Healthcare's technology to virtually track hospital patients. GE Healthcare invested in Decisio in 2019.

Until January 31, 2021, the Mural coronavirus bundle is being provided at no cost to hospitals. Among the users is Oregon Health & Science University in Portland.

"We're trying to carry as much of the cost burden to make this as sustainable as possible for our hospital partners that we know are hurting economically right now," says Bryan Haardt, CEO of Decisio.

"There has to be a moralistic compass," he adds. "You have to be driven by something more than just profit."

GE Healthcare, which contributed to Decisio's $13 million Series B round in December, was already partnering with the startup on the Mural Virtual Care Solution. Microsoft was brought into the mix to speed up delivery of the platform in response to the coronavirus pandemic.

"This relationship did not exist prior to this initiative," Haardt says. "We all came together and said, 'Guys, we've got to do our part. It is absolutely a moral imperative that we get together.' And we said, 'OK, well, what are the parts?'"

Haardt says this project equips hospitals to adhere to the best standards of care when it comes to treating COVID-19 patients who are relying on ventilators. In a COVID-19 treatment setting, one of the key benefits of the Mural Virtual Care Solution is that a health care clinician can monitor a patient's vital signs and other data without physical contact, he says.

Founded in 2013, Decisio built its virtual health platform using technology licensed from and developed at the University of Texas Health Science Center in Houston. Coupling real-time clinical surveillance with data visualization, the DECISIOInsight software can pinpoint risks and guide clinicians toward better decisions about patient care.

Haardt says Decisio's software aims to reduce the rate of hospital deaths, length of hospital stays, and burden on hospital resources by helping health care providers decrease the severity of hospital-acquired infections, pneumonia, the flu, and other conditions. Baylor St. Luke's Medical Center in Houston is among the customers for Decisio and GE Healthcare's broad-based Mural Virtual Care Solution, which was rolled out last year.

Also, Decisio has teamed up with professional services firm Deloitte to deliver virtual patient monitoring at U.S. Department of Defense hospitals. This technology is being piloted at Brooke Army Medical Center in San Antonio and Naval Medical Center San Diego.

"We look at doctors and nurses as heroes, because they're really good at getting people out of trouble," Haardt says. "And we like to think of our solution as keeping people out of trouble, because if you can keep them out of the trouble, then these heroic, herculean efforts [by doctors and nurses] are not required as much … ."

Haardt explains that Decisio's technology can monitor patient activity and detect patient trends in not just one area of a hospital (such as an ICU) or throughout an entire hospital but across a commonly managed group of hospitals. Those insights help hospitals ensure all of their health care professionals are following the same treatment protocols.

The No. 1 economic detriment to hospitals "is doing things different at all their different facilities," Haardt says. "If you can reduce the variability of care, we know the cost to provide goods and services goes down, and we know the outcomes improve."

Decisio Health Inc. is designing data-driven resources for clinicians and patients using virtual care. Photo via decisiohealth.com

Houston virtual health care company receives investment from GE for its $13M series B

Money moves

A Houston-based health tech company is wrapping up its series B fundraising round with an investment from Chicago-based GE Healthcare.

The fundraising round is in its initial closing, says Gray Hancock, COO Decisio Health Inc., and is expected to close at $13 million. Decisio has previously raised $7 million, according to Crunchbase. The funds will be used for product development, support, and ongoing growth in operations.

"This investment really cements our partnership with GE Healthcare," Hancock tells InnovationMap in an email. "We signed a global distribution agreement with them earlier this year, so the investment is another step forward in our strategic alignment."

GE Healthcare also invested in Massachusetts-based Formlabs, which makes low-cost 3D printers for anatomical models, and U.K.-based CMR Surgical Ltd., which specializes in surgical robotics.

"Healthcare's next chapter will be written in part by emerging technologies like 3D printing, robotic surgery and virtual patient monitoring," says Kieran Murphy, president and CEO of GE Healthcare, in a news release. "That's why we're putting GE Healthcare's innovative engine and resources behind collaborations with these exciting, next generation companies – to help change the way clinicians work and enable more precise patient care."

Decisio is a virtual care monitoring software that was founded in 2013 based on technology licensed from and developed at the University of Texas Health Science Center in Houston. Using real-time clinical surveillance with data visualization, the DECISIOInsight software can identify risk that helps clinicians make better patient care decisions virtually.

"Our theory was that if you can make the clinicians job's easier, and improve the outcomes for the patients then costs will come down," Hancock says. "But the care of the patient comes first. Do that right and the cost savings will follow. We say its 'where outcomes meet income.'"

In 2015, Decisio Health was approved by the Food and Drug Administration class II medical device, which made it the first FDA-cleared web-native software.

For Decisio, the future of health care is virtual, and the company is determined to design the best technology for clinicians and patients alike.

"Virtual Care is the next step beyond traditional telemedicine, which — for many years — was limited to having a teleconference or even just a phone call with a caregiver," Hancock says. "Now we can start sharing real-time clinical data with clinicians wherever they happen to be located."

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston founder on shaping the future of medicine through biotechnology and resilience

Guest Column

Living with chronic disease has shaped my life in profound ways. My journey began in 5th grade when I was diagnosed with Scheuermann’s disease, a degenerative disc condition that kept me sidelined for an entire year. Later, I was diagnosed with hereditary neuropathy with liability to pressure palsies (HNPP), a condition that significantly impacts nerve recovery. These experiences didn’t just challenge me physically, they reshaped my perspective on healthcare — and ultimately set me on my path to entrepreneurship. What started as personal health struggles evolved into a mission to transform patient care through innovative biotechnology.

A defining part of living with these conditions was the diagnostic process. I underwent nerve tests that involved electrical shocks to my hands and arms — without anesthesia — to measure nerve activity. The pain was intense, and each test left me thinking: There has to be a better way. Even in those difficult moments, I found myself thinking about how to improve the tools and processes used in healthcare.

HNPP, in particular, has been a frustrating condition. For most people, sleeping on an arm might cause temporary numbness that disappears in an hour. For me, that same numbness can last six months. Even more debilitating is the loss of strength and fine motor skills. Living with this reality forced me to take an active role in understanding my health and seeking solutions, a mindset that would later shape my approach to leadership.

Growing up in Houston, I was surrounded by innovation. My grandfather, a pioneering urologist, was among the first to introduce kidney dialysis in the city in the 1950s. His dedication to advancing patient care initially inspired me to pursue medicine. Though my path eventually led me to healthcare administration and eventually biotech, his influence instilled in me a lifelong commitment to medicine and making a difference.

Houston’s thriving medical and entrepreneurial ecosystems played a critical role in my journey. The city’s culture of innovation and collaboration provided opportunities to explore solutions to unmet medical needs. When I transitioned from healthcare administration to founding biotech companies, I drew on the same resilience I had developed while managing my own health challenges.

My experience with chronic disease also shaped my leadership philosophy. Rather than accepting diagnoses passively, I took a proactive approach questioning assumptions, collaborating with experts, and seeking new solutions. These same principles now guide decision-making at FibroBiologics, where we are committed to developing groundbreaking therapies that go beyond symptom management to address the root causes of disease.

The resilience I built through my health struggles has been invaluable in navigating business challenges. While my early career in healthcare administration provided industry insights, launching and leading companies required the same determination I had relied on in my personal health journey.

I believe the future of healthcare lies in curative treatments, not just symptom management. Fibroblast cells hold the promise of engaging the body’s own healing processes — the most powerful cure for chronic diseases. Cell therapy represents both a scientific breakthrough and a significant business opportunity, one that has the potential to improve patient outcomes while reducing long-term healthcare costs.

Innovation in medicine isn’t just about technology; it’s about reimagining what’s possible. The future of healthcare is being written today. At FibroBiologics, our mission is driven by more than just financial success. We are focused on making a meaningful impact on patients’ lives, and this purpose-driven approach helps attract talent, engage stakeholders, and differentiate in the marketplace. Aligning business goals with patient needs isn’t just the right thing to do, it’s a powerful model for sustainable growth and lasting innovation in biotech.

---

Pete O’Heeron is the CEO and founder of FibroBiologics, a Houston-based regenerative medicine company.


Houston researchers make headway on affordable, sustainable sodium-ion battery

Energy Solutions

A new study by researchers from Rice University’s Department of Materials Science and NanoEngineering, Baylor University and the Indian Institute of Science Education and Research Thiruvananthapuram has introduced a solution that could help develop more affordable and sustainable sodium-ion batteries.

The findings were recently published in the journal Advanced Functional Materials.

The team worked with tiny cone- and disc-shaped carbon materials from oil and gas industry byproducts with a pure graphitic structure. The forms allow for more efficient energy storage with larger sodium and potassium ions, which is a challenge for anodes in battery research. Sodium and potassium are more widely available and cheaper than lithium.

“For years, we’ve known that sodium and potassium are attractive alternatives to lithium,” Pulickel Ajayan, the Benjamin M. and Mary Greenwood Anderson Professor of Engineering at Rice, said in a news release. “But the challenge has always been finding carbon-based anode materials that can store these larger ions efficiently.”

Lithium-ion batteries traditionally rely on graphite as an anode material. However, traditional graphite structures cannot efficiently store sodium or potassium energy, since the atoms are too big and interactions become too complex to slide in and out of graphite’s layers. The cone and disc structures “offer curvature and spacing that welcome sodium and potassium ions without the need for chemical doping (the process of intentionally adding small amounts of specific atoms or molecules to change its properties) or other artificial modifications,” according to the study.

“This is one of the first clear demonstrations of sodium-ion intercalation in pure graphitic materials with such stability,” Atin Pramanik, first author of the study and a postdoctoral associate in Ajayan’s lab, said in the release. “It challenges the belief that pure graphite can’t work with sodium.”

In lab tests, the carbon cones and discs stored about 230 milliamp-hours of charge per gram (mAh/g) by using sodium ions. They still held 151 mAh/g even after 2,000 fast charging cycles. They also worked with potassium-ion batteries.

“We believe this discovery opens up a new design space for battery anodes,” Ajayan added in the release. “Instead of changing the chemistry, we’re changing the shape, and that’s proving to be just as interesting.”

---

This story originally appeared on EnergyCapitalHTX.com.

FAA demands investigation into SpaceX's out-of-control Starship flight

Out of this world

The Federal Aviation Administration is demanding an accident investigation into the out-of-control Starship flight by SpaceX on May 27.

Tuesday's test flight from Texas lasted longer than the previous two failed demos of the world's biggest and most powerful rocket, which ended in flames over the Atlantic. The latest spacecraft made it halfway around the world to the Indian Ocean, but not before going into a spin and breaking apart.

The FAA said Friday that no injuries or public damage were reported.

The first-stage booster — recycled from an earlier flight — also burst apart while descending over the Gulf of Mexico. But that was the result of deliberately extreme testing approved by the FAA in advance.

All wreckage from both sections of the 403-foot (123-meter) rocket came down within the designated hazard zones, according to the FAA.

The FAA will oversee SpaceX's investigation, which is required before another Starship can launch.

CEO Elon Musk said he wants to pick up the pace of Starship test flights, with the ultimate goal of launching them to Mars. NASA needs Starship as the means of landing astronauts on the moon in the next few years.